Why Is GILEAD SCIENCES INC (GILD) Stock Moving Today?

GILD stock is moving modestly higher in early trading following the European Commission’s approval of Gilead’s Trodelvy in combination with Keytruda for first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. The approval expands the drug’s role in Europe and comes amid strong performance in Gilead’s HIV business and broader commercial momentum across its oncology and liver disease divisions.

What Happened

The European Commission granted marketing authorization for Gilead’s Trodelvy plus Merck’s Keytruda for first-line PD-L1-positive metastatic triple-negative breast cancer. This follows a Phase 3 ASCENT-04 study showing a 35% lower risk of progression or death for patients receiving the combination. The approval is a significant milestone for Gilead’s oncology portfolio, which has treated more than 75,000 breast cancer patients globally with Trodelvy. The move adds to recent positive developments for the company, including strong fiscal Q2 2026 results with total revenue rising 10% year over year to approximately $7.8 billion.

What The Data Shows

GILD opened with a +0.5% gap from the prior close and reached an intraday high of $147.00 before retreating to $146.44 in late morning trading. Volume has been subdued at 1.3 million shares, or 0.2 times the 3-month daily average. The stock remains within its 52-week range of $108.46 to $157.29. On the fundamentals, Gilead has a market cap of $181.2 billion, with unprofitable earnings (TTM EPS -2.61), revenue up 5.5% TTM, and a net margin of -10.6%. The stock’s beta of 0.34 indicates low volatility relative to the market.

What To Watch

Gilead’s upcoming earnings report will be a key event for investors. Until then, the broader biotech sector and coverage of its HIV and oncology pipelines will be important to monitor.

Why is GILD stock moving today?

GILEAD SCIENCES INC (GILD) is drawing unusual attention today. Our newswire has captured 1 story on GILD across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 72/100). The most recent driver: "Why Did MO, GILD, XOM Stocks Surge To 52-Week Highs Last Week?" (Stocktwits News).

Is GILD a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of GILD coverage reads 72/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.